In this episode, Joel M. Gelfand, MD, MSCE, and Leonard H. Calabrese, DO, are joined by Paul E. Sax, MD, as they discuss advances in the outpatient management of COVID-19 and emerging information about the omicron variant.

• Welcome from Joel Gelfand, MD, MSCE :10
• About Calabrese, Gelfand and Sax :25
• A quick update since the last webinar :51
• Sax’s thoughts on the effectiveness of monoclonal antibodies 1:46
• What are the situations where we should be thinking about postexposure prophylaxis with these agents? 7:06
• When you start using pre-exposure prophylaxis therapy, how would you counsel the patients receiving it? 12:56
• How does Merck’s molnupiravir work? 17:22
• Sax’s thoughts on Pfizer’s paxlovid 22:23
• What’s your perspective on fluvoxamine? Does it work? 25:26
• Paul, what have you learned so far about the omicron variant? 30:15
• How much more contagious is this than Delta and what would you compare it to? 31:09
• Questions from the audience 35:27
• Tweet your questions @DrJoelGelfand, @LCalabreseDO and @PaulSaxMD. 38:35

Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer Chair of Clinical Immunology at the Cleveland Clinic.

Joel M. Gelfand, MD, MSCE, is chief medical editor of Healio Psoriatic Disease and professor of dermatology and epidemiology at the Perelman School of Medicine at the University of Pennsylvania. He is also vice chair of clinical research, medical director at the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine.

Paul E. Sax, MD, is clinical director of the Infectious Disease Clinic and professor of medicine at Harvard Medical School.

We’d love to hear from you! Send your comments/questions to Drs. Gelfand, Calabrese and Sax at [email protected]. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @PaulSaxMD.

Disclosures: Calabrese reports consulting for AstraZeneca, GSK and Regeneron. Gelfand and Sax report no relevant financial disclosures.